Program
EGFR/EGFRvIII Inhibitor WSD0922-FU
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Wayshine Biopharm.
Drug pageEGFR/EGFRvIII Inhibitor WSD0922-FU: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 2, since Aug 25, 20242 company-led studies, 2 open or runningNext primary completion: Jun 30, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Wayshine Biopharm | 22 open or running | phase 2since Aug 25, 2024 | Aug 25, 2024 | Jun 30, 2027phase 2 · NCT06631989 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 25, 2024First study: phase 2 study in EGFR Mutation Positive Advanced Non-Small Cell Lung CancerFirst studyNCT06631989 · 60 enrolled · China
- Sep 19, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07206498 · 48 planned · China
Ahead
- Jun 30, 2027Primary completion: phase 2 study in EGFR Mutation Positive Advanced Non-Small Cell Lung CancerNCT06631989
- Oct 14, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07206498
TargetBeta
EGFR →read by rule
“A blood-brain-barrier (BBB) penetrable selective inhibitor of epidermal growth factor receptor (EGFR) and various EGFR mutations, including but not limited to the EGFR variant III (EGFRvIII) mutant form, ”NCIt, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| befotertinibrule | Betta Pharmaceuticals | phase 3 | 6 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07206498Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Oct 14, 2028 | 48 |
| NCT06631989EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer · China | 2 | Active, not recruiting | Jun 30, 2027 | 60 |
How it is read
Names in the registry
- “WSD0922-FU”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.